: Contraindicated in patients with symptomatic heart failure or recent hospitalization for heart failure (NYHA Class IV or symptomatic Class II-III).
Following the ATHENA results, dronedarone was approved with specific administration and safety protocols. : The only recommended dose is 400 mg twice daily . ATHENA HEART [310]
: Do not use in patients who cannot or will not be converted to sinus rhythm. : Contraindicated in patients with symptomatic heart failure
Based on the code , this guide provides a breakdown of the ATHENA clinical trial (A Trial with dronedarone to prevent Hospitalization or death in patients with Atrial fibrillation) and the associated use of dronedarone (brand name Multaq ) for cardiovascular health. 1. Overview of the ATHENA Trial : Do not use in patients who cannot
It is intended to reduce the risk of hospitalization for AF. 3. Safety and Contraindications